These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 32562276)

  • 1. Statins: Could an old friend help in the fight against COVID-19?
    Rodrigues-Diez RR; Tejera-Muñoz A; Marquez-Exposito L; Rayego-Mateos S; Santos Sanchez L; Marchant V; Tejedor Santamaria L; Ramos AM; Ortiz A; Egido J; Ruiz-Ortega M
    Br J Pharmacol; 2020 Nov; 177(21):4873-4886. PubMed ID: 32562276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The hidden role of NLRP3 inflammasome in obesity-related COVID-19 exacerbations: Lessons for drug repurposing.
    Bertocchi I; Foglietta F; Collotta D; Eva C; Brancaleone V; Thiemermann C; Collino M
    Br J Pharmacol; 2020 Nov; 177(21):4921-4930. PubMed ID: 32776354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The case for chronotherapy in Covid-19-induced acute respiratory distress syndrome.
    Tamimi F; Abusamak M; Akkanti B; Chen Z; Yoo SH; Karmouty-Quintana H
    Br J Pharmacol; 2020 Nov; 177(21):4845-4850. PubMed ID: 32442317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-steroidal anti-inflammatory drugs, prostaglandins, and COVID-19.
    Robb CT; Goepp M; Rossi AG; Yao C
    Br J Pharmacol; 2020 Nov; 177(21):4899-4920. PubMed ID: 32700336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A rationale for targeting the P2X7 receptor in Coronavirus disease 19.
    Di Virgilio F; Tang Y; Sarti AC; Rossato M
    Br J Pharmacol; 2020 Nov; 177(21):4990-4994. PubMed ID: 32441783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Animal models of mechanisms of SARS-CoV-2 infection and COVID-19 pathology.
    Cleary SJ; Pitchford SC; Amison RT; Carrington R; Robaina Cabrera CL; Magnen M; Looney MR; Gray E; Page CP
    Br J Pharmacol; 2020 Nov; 177(21):4851-4865. PubMed ID: 32462701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A hypothesis for pathobiology and treatment of COVID-19: The centrality of ACE1/ACE2 imbalance.
    Sriram K; Insel PA
    Br J Pharmacol; 2020 Nov; 177(21):4825-4844. PubMed ID: 32333398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting zinc metalloenzymes in coronavirus disease 2019.
    Doboszewska U; Wlaź P; Nowak G; Młyniec K
    Br J Pharmacol; 2020 Nov; 177(21):4887-4898. PubMed ID: 32671829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A lesson from a saboteur: High-MW kininogen impact in coronavirus-induced disease 2019.
    Colarusso C; Terlizzi M; Pinto A; Sorrentino R
    Br J Pharmacol; 2020 Nov; 177(21):4866-4872. PubMed ID: 32497257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development: IUPHAR Review 29.
    Alexander SPH; Armstrong JF; Davenport AP; Davies JA; Faccenda E; Harding SD; Levi-Schaffer F; Maguire JJ; Pawson AJ; Southan C; Spedding M
    Br J Pharmacol; 2020 Nov; 177(21):4942-4966. PubMed ID: 32358833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteinase-activated receptor 1: A target for repurposing in the treatment of COVID-19?
    Sriram K; Insel PA
    Br J Pharmacol; 2020 Nov; 177(21):4971-4974. PubMed ID: 32639031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-inflammatory and antiviral roles of hydrogen sulfide: Rationale for considering H
    Citi V; Martelli A; Brancaleone V; Brogi S; Gojon G; Montanaro R; Morales G; Testai L; Calderone V
    Br J Pharmacol; 2020 Nov; 177(21):4931-4941. PubMed ID: 32783196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential of cannabidiol in the COVID-19 pandemic.
    Esposito G; Pesce M; Seguella L; Sanseverino W; Lu J; Corpetti C; Sarnelli G
    Br J Pharmacol; 2020 Nov; 177(21):4967-4970. PubMed ID: 32519753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current pharmacological treatments for COVID-19: What's next?
    Scavone C; Brusco S; Bertini M; Sportiello L; Rafaniello C; Zoccoli A; Berrino L; Racagni G; Rossi F; Capuano A
    Br J Pharmacol; 2020 Nov; 177(21):4813-4824. PubMed ID: 32329520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 treatment by repurposing drugs until the vaccine is in sight.
    Phadke M; Saunik S
    Drug Dev Res; 2020 Aug; 81(5):541-543. PubMed ID: 32227357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study].
    Plaze M; Attali D; Petit AC; Blatzer M; Simon-Loriere E; Vinckier F; Cachia A; Chrétien F; Gaillard R
    Encephale; 2020 Jun; 46(3S):S35-S39. PubMed ID: 32387014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents.
    Khadke S; Ahmed N; Ahmed N; Ratts R; Raju S; Gallogly M; de Lima M; Sohail MR
    Virol J; 2020 Oct; 17(1):154. PubMed ID: 33059711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.
    Zhang X; Zhang Y; Qiao W; Zhang J; Qi Z
    Int Immunopharmacol; 2020 Sep; 86():106749. PubMed ID: 32645632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pros and cons for use of statins in people with coronavirus disease-19 (COVID-19).
    Subir R; Jagat J M; Kalyan K G
    Diabetes Metab Syndr; 2020; 14(5):1225-1229. PubMed ID: 32683320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using
    Choudhary S; Malik YS; Tomar S
    Front Immunol; 2020; 11():1664. PubMed ID: 32754161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.